目的 评价南京地区2017—2019年乳腺癌内分泌治疗药物的临床应用情况和变化趋势。方法 对南京地区41家医疗机构2017—2019年乳腺癌内分泌治疗药物的品种、销售金额、用药频度（DDDs）等进行统计和分析。结果 乳腺癌内分泌治疗药物的销售总金额和年DDDs逐年增长，平均年增长率分别为12.22%和13.89%。戈舍瑞林、亮丙瑞林、阿那曲唑等药物连续3年排在销售金额前3位，且占总销售金额的70%左右。他莫昔芬、来曲唑、戈舍瑞林等药物连续3年排在DDDs值前3位，且超过总DDDs值的50%。其中氟维司群的增长最为显著。结论 南京乳腺癌内分泌治疗药物床应用广泛，使用量和金额均稳步增长，绝大部分药物的DDC呈降低趋势。

Objective To evaluate the clinical application and trends of endocrine therapy drugs for breast cancer in Nanjing area from 2017 to 2019. Methods Statistics and analysis of endocrine therapy drugs for breast cancer, sales amount and frequency of drug use (DDDs) were carried out in 41 hospitals in Nanjing area from 2017 to 2019. Results The total sales and DDDs of endocrine therapy drugs for breast cancer increased year by year, with an average annual growth rate of 12.22% and 13.89%, respectively. The drugs of goserelin, leuprorelin, and anastrozole were ranked in the top 3 of the sales amount and the total sales amount was about 70%, while tamoxifen, letrozole, and goserelinwere ranked in the top 3 of the DDDs, and the total DDDs ratio exceeded 50%. Fulvestran increased most significantly. Conclusion The endocrine therapydrugs for breast cancer are widely used in Nanjing area, both the usage and the amount are showing in a steadily growth trend, while the daily drug cost (DDC) of most drugs is in a decreasing trend.

R979.1

江苏省软科学研究项目（BR2020043）；南京大学医院管理研究所管理项目课题（NDYG2019006）；中国药学会科技开发中心科普项目（CMEI2020KPYJ（JZX）00412）